Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and immunogenicity of the Cuban heptavalent pneumococcal conjugate vaccine in healthy infants. Results from a double-blind randomized control trial Phase I.
Martínez CPD, Linares-Pérez N, Toledo-Romaní ME, Delgado YR, Gómez RP, Moreno BP, Rodriguez-Noda LM, Sosa MM, Mederos DS, García-Rivera D, Valdés-Balbín Y, Goldblatt D, Vérez-Bencomo V; Havana-Pneumococci Clinical Group; Finlay-Pneumococci Project. Martínez CPD, et al. Vaccine. 2018 Aug 6;36(32 Pt B):4944-4951. doi: 10.1016/j.vaccine.2018.05.027. Epub 2018 Jul 10. Vaccine. 2018. PMID: 30005948 Clinical Trial.
Cost-effectiveness of introducing a domestic pneumococcal conjugate vaccine (PCV7-TT) into the Cuban national immunization programme.
García Fariñas A, Linares-Pérez N, Clark A, Toledo-Romaní ME, Omeiri NE, Marrero Araújo MC, Gonzálvez Luis IP, Toraño Peraza G, Reyes Jiménez A, López Ambrón L; Cuban Pneumococcal Vaccine Working Group. García Fariñas A, et al. Int J Infect Dis. 2020 Aug;97:182-189. doi: 10.1016/j.ijid.2020.05.078. Epub 2020 May 29. Int J Infect Dis. 2020. PMID: 32474199 Free article.
Corrigendum to "Cost-effectiveness of introducing a domestic pneumococcal conjugate vaccine (PCV7-TT) into the Cuban national immunization programme" [Int. J. Infect. Dis. 97 (2020) 182-189].
Fariñas AG, Linares-Pérez N, Clark A, Toledo-Romaní ME, Omeiri NE, Araújo MCM, Luis IPG, Peraza GT, Jiménez AR, Ambrón LL; Cuban Pneumococcal Vaccine Working Group. Fariñas AG, et al. Int J Infect Dis. 2021 Feb;103:643. doi: 10.1016/j.ijid.2020.08.072. Epub 2020 Nov 26. Int J Infect Dis. 2021. PMID: 33250353 Free article. No abstract available.
Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults.
Toledo-Romani ME, García-Carmenate M, Verdecia-Sánchez L, Pérez-Rodríguez S, Rodriguez-González M, Valenzuela-Silva C, Paredes-Moreno B, Sanchez-Ramirez B, González-Mugica R, Hernández-Garcia T, Orosa-Vázquez I, Díaz-Hernández M, Pérez-Guevara MT, Enriquez-Puertas J, Noa-Romero E, Palenzuela-Diaz A, Baro-Roman G, Mendoza-Hernández I, Muñoz Y, Gómez-Maceo Y, Santos-Vega BL, Fernandez-Castillo S, Climent-Ruiz Y, Rodríguez-Noda L, Santana-Mederos D, García-Vega Y, Chen GW, Doroud D, Biglari A, Boggiano-Ayo T, Valdés-Balbín Y, Rivera DG, García-Rivera D, Vérez-Bencomo V; SOBERANA Research Group. Toledo-Romani ME, et al. Med. 2022 Nov 11;3(11):760-773.e5. doi: 10.1016/j.medj.2022.08.001. Epub 2022 Aug 8. Med. 2022. PMID: 35998623 Free PMC article. Clinical Trial.
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children.
Puga-Gómez R, Ricardo-Delgado Y, Rojas-Iriarte C, Céspedes-Henriquez L, Piedra-Bello M, Vega-Mendoza D, Pérez NP, Paredes-Moreno B, Rodríguez-González M, Valenzuela-Silva C, Sánchez-Ramírez B, Rodríguez-Noda L, Pérez-Nicado R, González-Mugica R, Hernández-García T, Fundora-Barrios T, Echevarría MD, Enriquez-Puertas JM, Infante-Hernández Y, Palenzuela-Díaz A, Gato-Orozco E, Chappi-Estévez Y, Francisco-Pérez JC, Suarez-Martinez M, Castillo-Quintana IC, Fernandez-Castillo S, Climent-Ruiz Y, Santana-Mederos D, García-Vega Y, Toledo-Romani ME, Doroud D, Biglari A, Valdés-Balbín Y, García-Rivera D, Vérez-Bencomo V; SOBERANA Research Group. Puga-Gómez R, et al. Among authors: toledo romani me. Int J Infect Dis. 2023 Jan;126:164-173. doi: 10.1016/j.ijid.2022.11.016. Epub 2022 Nov 18. Int J Infect Dis. 2023. PMID: 36403819 Free PMC article. Clinical Trial.
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial.
Toledo-Romaní ME, García-Carmenate M, Valenzuela-Silva C, Baldoquín-Rodríguez W, Martínez-Pérez M, Rodríguez-González M, Paredes-Moreno B, Mendoza-Hernández I, González-Mujica Romero R, Samón-Tabio O, Velazco-Villares P, Bacallao-Castillo JP, Licea-Martín E, Rodríguez-Ortega M, Herrera-Marrero N, Caballero-González E, Egües-Torres L, Duartes-González R, García-Blanco S, Pérez-Cabrera S, Huete-Ferreira S, Idalmis-Cisnero K, Fonte-Galindo O, Meliá-Pérez D, Rojas-Remedios I, Doroud D, Gouya MM, Biglari A, Fernández-Castillo S, Climent-Ruiz Y, Valdes-Balbín Y, García-Rivera D, Van der Stuyft P, Verez-Bencomo V; SOBERANA Phase 3 team. Toledo-Romaní ME, et al. Lancet Reg Health Am. 2023 Feb;18:100423. doi: 10.1016/j.lana.2022.100423. Epub 2022 Dec 31. Lancet Reg Health Am. 2023. PMID: 36618081 Free PMC article.
Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals.
Eybpoosh S, Biglari A, Sorouri R, Ashrafian F, Sadat Larijani M, Verez-Bencomo V, Toledo-Romani ME, Valenzuela Silva C, Salehi-Vaziri M, Dahmardeh S, Doroud D, Banifazl M, Mostafavi E, Bavand A, Ramezani A. Eybpoosh S, et al. Among authors: toledo romani me. PLoS Pathog. 2023 Nov 1;19(11):e1011744. doi: 10.1371/journal.ppat.1011744. eCollection 2023 Nov. PLoS Pathog. 2023. PMID: 37910480 Free PMC article.
Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2-11 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population study.
Toledo-Romaní ME, Valenzuela-Silva C, Montero-Díaz M, Iñiguez-Rojas L, Rodríguez-González M, Martínez-Cabrera M, Puga-Gómez R, German-Almeida A, Fernández-Castillo S, Climent-Ruiz Y, Santana-Mederos D, López-González L, Morales-Suárez I, Doroud D, Valdés-Balbín Y, García-Rivera D, Van der Stuyft P, Vérez-Bencomo V. Toledo-Romaní ME, et al. Lancet Reg Health Am. 2024 Apr 23;34:100750. doi: 10.1016/j.lana.2024.100750. eCollection 2024 Jun. Lancet Reg Health Am. 2024. PMID: 38699214 Free PMC article.
18 results